Back to Top Skip to main content Skip to sub-navigation

DOD participates in new COVID-19 antibody combination prevention trial

Woman gets blood drawn Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | MHS Toolkits and Branding Guidance

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

More Than 95% of Active Duty Have Received COVID-19 Vaccine

Article
10/15/2021
Female hospital corpsman gives a COVID-19 vaccine injection to a sailor in her left arm

Service members continue to line up for COVID-19 vaccinations.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus | COVID-19 Information for Military Treatment Facility Directors

USECAF receives insight into COVID19 vaccinations at Reserve wing

Article Around MHS
10/8/2021
Under Secretary of the Air Force Gina Ortiz Jones visits with 433rd Airlift Wing members at Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio-Lackland, Texas, Oct. 2, 2021.

Under Secretary of the Air Force Gina Ortiz Jones visited the 433rd Airlift Wing here to meet with Reserve Citizen Airmen leaders on mandatory COVID-19 vaccination efforts, Oct. 2, 2021.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus

Mask Mouth Does Not Exist, Dentists Say

Article
10/6/2021
A bunch of children wearing face masks walk on a city street.

Mask mouth doesn’t exist, Internet chatter to the contrary, dentists say.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Compassionate Caring with COVID Vax Commitment

Article Around MHS
10/6/2021
A  female doctor poses for a photo.

When pregnant patients have an appointment with Lt. Cmdr. Megan Northup at Naval Hospital Bremerton, they get more than a qualified and caring OB/GYN physician.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

Health Promotion duo optimizes health on Incirlik Air Base

Article Around MHS
9/30/2021
Air Force Capt. Sydney Sloan, 39th Operational Medical Readiness Squadron health promotion element chief (right), and Air Force Senior Airman Gloriann Manapsal, 39th Operational Medical Readiness Squadron health promotion technician (left), promote making healthy choices at the Sultan’s Inn Dining Facility on Incirlik Air Base, Turkey.

The 39th Operation Medical Readiness Squadron health promotion team provides and integrates evidence-based programs to optimize the health and readiness, even during these unprecedented times.

Recommended Content:

Health Readiness | Total Force Fitness | Coronavirus

COVID-19 Booster Shots are Now Available – What You Need to Know

Article
9/30/2021
Containers of the Pfizer COVID-19 vaccine. Each vial contains six doses for vaccination against the COVID-19 virus.

Booster shots are now recommended for millions of people – but many others will have to wait for additional approvals.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Myths & facts about the vax - debunking common COVID-19 vaccine myths

Article
9/29/2021
Myths and facts about the vax

The COVID-19 vaccine has been mandated across the Department of Defense and despite its demonstrated effectiveness and safety, a host of myths have left some Airmen and Guardians hesitant to receive it. While social media posts and some news outlets may make it harder to keep up with what is fact or fiction, the science is clear … approved COVID-19 vaccines work.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Retired colonel leads Fort Irwin COVID response mission

Article Around MHS
9/28/2021
Army Col. Richard Hopkins, the COVID-19 response coordinator with Weed Army Community Hospital, collects paperwork from a Soldier who received the COVID-19 vaccine at a vaccination event.

Retired Army Col. Richard Hopkins volunteered under the Army’s COVID-19 Retiree Recall Program to return to service as the COVID-19 response coordinator for Weed Army Community Hospital and Fort Irwin, California.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

ARNORTH military support to FEMA begins in Tennessee, continues in five states

Article Around MHS
9/24/2021
Prepared COVID-19 vaccine shots wait to be administered to an Airman. Members of the 134th Air Refueling Wing were eligible to receive their COVID-19 vaccines during Unit Training Assembly here May 2nd, 2021.

At the request of the Federal Emergency Management Agency, approximately 20 military medical personnel deployed to Tennessee to support civilian healthcare workers treating COVID-19 patients in local hospitals.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

DODEA Schools Keeps On With In-Person Classes, and Fall Sports, Too

Article
9/23/2021
Kids playing football

DODEA schools are striving to continue in-person learning in the 2021-22 school year.

Recommended Content:

Children's Health | Coronavirus

COVID-19 can lead to long-term health concerns

Article Around MHS
9/23/2021
Debra Lamb, a 30-year civil service veteran at Ft. Carson, contracted the COVID-19 virus late in 2020 and experienced a harrowing ordeal before partially recovering months later.

Debra Lamb, a 30-year civil service veteran at Ft. Carson, contracted the COVID-19 virus late in 2020 and experienced a harrowing ordeal before partially recovering months later.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

6th Medical Group Delivers Mandatory Vaccines

Article Around MHS
9/21/2021
An Airman from the 6th Medical Group prepares a COVID-19 vaccine for distribution at MacDill Air Force Base, Florida.

Airmen from the 6th Medical Group began redistributing doses of the COVID-19 vaccine at MacDill Air Force Base, Florida, on Sept. 9, 2021. This comes after the Secretary of Defense issued a memorandum on Aug. 23, 2021, mandating all active duty personnel to be fully vaccinated against COVID-19.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

Got Your 6

Video
9/16/2021
Got Your 6 Infographic

‘Got Your 6’ is TRICARE’s COVID vaccine video series that delivers important information and updates, on days that end in ‘6.’ It includes the latest information about DOD vaccine distribution, the TRICARE health benefit, and vaccine availability. Got a question about ‘Got Your 6’? Send an email to dha.ncr.comm.mbx.dha-internal-communications@mail.mil

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

After the ventilator COVID survivor advocates for vaccine

Article Around MHS
9/15/2021
Tim Harris is sedated while on a ventilator

Tim Harris, a mobilization and planning specialist, U.S. Army Medical Center of Excellence, is sedated while on a ventilator at Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, Texas, June 27, 2020.

Recommended Content:

Coronavirus

Army Medicine Europe Provides Additional COVID Vaccinations for Immune Compromised

Article Around MHS
9/13/2021
Franz Dietrich, a German local national assigned to Training Support Activity Europe, receives a COVID-19 vaccination at the 7th Army Training Command's (7ATC) Rose Barracks, Vilseck, Germany, May 4, 2021. The U.S. Army Health Clinics at Grafenwoehr and Vilseck conducted a "One Community" COVID-19 vaccine drive May 3-7 to provide thousands of appointments to the 7ATC community of Soldiers, spouses, Department of the Army civilians, veterans and local nationals employed by the U.S. Army. (U.S. Army photo by Markus Rauchenberger)

Army medical treatment facilities in Europe are now offering an additional dose of COVID vaccine for immune compromised beneficiaries.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 41

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.